Real-World study tracks Ravulizumab's impact on rare kidney disease
NCT ID NCT07399730
First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study will follow about 80 Polish patients with atypical hemolytic uremic syndrome (aHUS) who are receiving ravulizumab (Ultomiris) as part of routine care. Researchers will collect data from medical records and follow patients over time to see how well the drug controls the disease, including its effects on blood clotting and kidney function. The goal is to understand real-world outcomes of ravulizumab treatment in this rare condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ravulizumab (Ultomiris)
- What this could lead to
- If successful, this study could confirm that ravulizumab effectively controls aHUS in real-world settings, helping maintain kidney function and reduce blood clotting complications.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It only includes Polish patients, so findings may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
NOT_YET_RECRUITINGGdansk, Poland
-
Research Site
NOT_YET_RECRUITINGKatowice, Poland
-
Research Site
RECRUITINGKatowice, Poland
-
Research Site
NOT_YET_RECRUITINGKrakow, Poland
-
Research Site
NOT_YET_RECRUITINGLodz, Poland
-
Research Site
NOT_YET_RECRUITINGPoznan, Poland
-
Research Site
RECRUITINGPoznan, Poland
-
Research Site
NOT_YET_RECRUITINGWarsaw, Poland
-
Research Site
RECRUITINGWarsaw, Poland
-
Research Site
NOT_YET_RECRUITINGWroclaw, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for aHUS patients: Long-Term iptacopan study launches
- Skin biopsies could unlock hidden genetic diagnoses
- New pill shows promise for rare blood disorder aHUS
- New drug ravulizumab aims to control rare blood disorder aHUS
- Promising aHUS drug trial stalls after only 6 patients enrolled
- New hope for kids with rare kidney disease: crovalimab trial underway